Lung adenocarcinoma presenting with an orbital metastasis

et al. 2022

Self Cite

Background: Histoplasmosis is a disease caused by fungus called Histoplasma capsulatum. Several studies reported cases of histoplasmosis that resembled malignancy [3]. . It is a fact that the clinical syndrome of neoplastic disease is not limited to malignancy, so that infectious diseases should be considered in the differential diagnosis. Method: This is descriptive research with consecutive samples. The sample was the patients with lung cancer aged 25-75 years old. The researcher assessed histoplasmic skin test on interdemal administered with fungal protein [5]. After being observed for allergic reaction in 48-72 hours, induration > 5mm shows positive reaction. The Result: this research included 25 samples consisting of 21 men and 4 women. The Result showed 1 person (4%) with positive histoplasmic skin test result containing squamous cell carcinoma and radiological features of solitary pulmonary nodule. There is an insignificant relationship between cancer cell types and the histoplasmic skin test results (p = 0.24). There is an insignificant relationship between histoplamic skin test result and radiological features (p = 0.48). The Conclusion: There is one person with positive histoplasmic skin test result with squamous cell carcinoma and radiological features of solitary pulmonary nodule.

Section: Discussionmentioning

confidence: 96%

The Prevalence of Histoplasmic Skin Test in Lung Cancer Patients

Afiani

et al. 2022

Self Cite

“…This study was focused on lung adenocarcinoma which had been increasing in numbers in recent years and research in Indonesia had focused on the advanced stage [15], [16], [17], or those had spread to other organs (metastatic) [18]. Study showed that smoking is independent risk factor for lung cancer, particularly in males, in which clove cigarettes are preferred choice [19].…”

Section: Discussionmentioning

confidence: 99%

Concordance of Epidermal Growth Factor Receptor Mutation from Tissue Biopsy and Plasma Circulating Tumor DNA in Treatment-Naïve Lung Adenocarcinoma Patients

Taufik

et al. 2022

Self Cite

Background: Prevalence of Epidermal Growth Factor Receptor (EGFR) mutation in ctDNA in treatment-naïve individuals are not well established in Indonesia. In recent years, ctDNA as a specific and sensitive blood-based biomarker had been developed to detect the mutation. The study was done to understand the concordance and acceptance levels of ctDNA in detecting the gene mutation in lung adenocarcinoma patients. Methods: This study used cross-sectional approach with purposive sampling design in 100 treatment-naïve NSCLC, adenocarcinoma patients. Samples were obtained from bronchoscopy, and blood, which were examined to detect the mutation in formalin-fixed, paraffin-embedded (FFPE) specimens or plasma samples using QIAampDNA Micro Kit. Mutation was calculated by droplet digital PCR (ddPCR). Results: A hundred subjects with primary tumor tissue samples were compared with the plasma samples and mutation was detected in 20 patients (20.0%), 12 (12.0%) on exon 19, 7 (7.0%) on exon 21 and 1 (1.0%) on both exon 19 and 21. Within the plasma samples, mutation was found in 15 patients (15%) with mutation on exon 19 and 21 in 12 (12.0%) and 3 (3.0%) patients, respectively. Within the two samples, concordance of EGFR mutation was 83.0% (83/100, P<0.001; correlation index: 0.42). Assuming presence of mutation as the benchmark, the accuracy of mutation presence in plasma DNA was 60.0% (9/15). Kappa test showed a weak agreement between the mutation in tissues and plasma, with a coefficient of 0.414 (95% CI). Conclusion: Tissue biopsy was still considered as the main option to detect EGFR mutation in lung cancer. More research on ctDNA as the standardized tools to detect the mutation are required.

“…Diagnosis can be very challenging in terms of clinical symptoms associated with distant metastases as the initial clinical manifestations found [19]. Soeroso et al also stated that the most rarely found metastasis is orbital metastasis, especially in adenocarcinoma subtype [20].…”

Section: Discussionmentioning

confidence: 99%

The Effectiveness of Bisphosphonate to Reduce Pain in Lung Cancer Patients with Bone Metastasis

Panggabean

et al. 2022

Self Cite

Background: Bisphosphonates (BPs) are commonly used as supportive therapy to prevent skeletal-related events in lung cancer patients with bone metastasis, including severe bone pain, hypercalcemia, and pathological fractures. The purpose of this study was to assess the effectiveness of bisphosphonate therapy to reduce pain in non-small cell lung cancer (NSCLC) patients with bone metastasis. Methods: This was a cross-sectional study carried on 38 patients diagnosed with lung cancer based on cytology or histopathology findings. Radiological examination such as thoracic CT scan, bone survey, and bone scan was performed to determine bone metastasis. Multimodality therapy is carried out for lung cancer palliative therapy including chemotherapy, radiotherapy, and bisphosphonate therapy (zoledronic acid and ibandronate) as supportive therapy to reducing cancer pain. Pain was assessed using the Visual Analog Scale (VAS) determined by patients themselves. Statistical tests were performed by paired T-test in which p< 0.05 was considered significant. Results: As many as 38 patients enrolled in this study consisting of 29 men (76.3%) and 9 women (23.7%). The subtype of adenocarcinoma was mostly found in 31 cases (81.58%) and 7 cases (18.42%) was Squamous Cell Carcinoma. Cancer pain was found in all patients. Measurement of pain prior to treatment showed that most patients had VAS level of 7-10. After bisphosphonate therapy, the VAS level significantly decreased to 1-3 (p<0.01). Conclusion: Bisphosphonate therapy was proven to effectively decrease the severity level of cancer pain in lung cancer patients with bone metastasis.